iBio updates corporate presentation, details pipeline milestones and $88M cash runway
iBio updated its corporate presentation highlighting next—gen obesity antibody programs, near—term IND/clinical milestones and $88.0M cash on hand.Key Highlights:Original SEC Filing: iBio, Inc. [ IBIO ] - 8-K - Sep. 14, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verify…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.